Key Takeaways
- Shares of Eli Lilly declined approximately 3% Monday following reports of a liver failure case linked to Foundayo in FDA adverse event records
- The reported case concerned a 56-year-old patient; Eli Lilly quickly refuted any connection to Foundayo
- Numerous Wall Street experts characterized the market response as exaggerated and recommended purchasing shares at reduced prices
- Since its debut last month, Foundayo has attracted 20,000 patients, with four-fifths being first-time GLP-1 users
- The pharmaceutical giant posted impressive quarterly results with Mounjaro revenue surging 125% to $8.6B and Zepbound climbing 80% to $4.1B
Shares of Eli Lilly experienced a roughly 3% decline Monday morning following comments from Evercore ISI’s Umer Raffat, who highlighted a hepatic failure entry in the FDA Adverse Event Reporting System (FAERS) connected to Foundayo, the company’s recently introduced oral GLP-1 medication.
The adverse event report detailed a case involving a 56-year-old male patient and potentially occurred on or prior to April 15. FDA records show the report was filed on April 30.
LLY shares traded around $934 during early Monday sessions before staging a partial rebound. Meanwhile, competitor Novo Nordisk (NVO) experienced approximately 2% gains following the disclosure.
Raffat emphasized that examining this single case in isolation would be inappropriate. He pointed out that hepatic failure reports exist across various GLP-1 medications — with Ozempic linked to 33 reports, Wegovy to 15, Mounjaro to 30, and Zepbound to 2.
He stated that responsibility falls on Lilly to guarantee thorough and expedient evaluation of liver-related cases to prevent uncertainty, particularly considering previous liver toxicity worries associated with alternative oral GLP-1 compounds, including Pfizer’s discontinued candidate.
Lilly responded swiftly to the emerging concern. Following internal review, the pharmaceutical company rejected any association between the reported case and Foundayo.
Alexandria Hammond from Wolfe Research supported Lilly’s assessment. She characterized the pre-market decline as “overdone” and indicated she would purchase shares during the weakness.
Bernstein’s Christian Moore expressed similar sentiment. He suggested that missing a liver toxicity indicator would be improbable considering the extensive clinical trial information compiled for Foundayo, adding that he planned to buy during the price dip.
Foundayo’s hepatic safety profile underwent evaluation across numerous studies, including the extensive ACHIEVE-4 trial involving 2,800 participants, which specifically examined hepatic safety at the FDA’s directive and identified no concerning signals.
Strong Early Adoption for Foundayo
Since launching last month, Foundayo has already enrolled 20,000 patients. Notably, 80% of these individuals represent first-time GLP-1 drug users, indicating the oral formulation is broadening market reach rather than simply shifting patients from injectable alternatives.
Foundayo offers a convenience advantage compared to Novo Nordisk’s oral Wegovy formulation — patients can take it without fasting requirements, simplifying integration into everyday schedules.
The pharmaceutical company is also expanding provider education efforts and improving distribution through mainstream pharmacy networks.
Robust Financial Performance Continues
Monday’s decline occurred despite Lilly delivering impressive quarterly earnings results the previous week. Mounjaro revenues soared 125% to reach $8.6 billion, while Zepbound increased 80% to $4.1 billion.
Eli Lilly commands approximately 60% of the U.S. GLP-1 medication market, supported partially by head-to-head clinical data demonstrating enhanced weight reduction compared to rival therapies.
The pharmaceutical company maintains development of several additional weight management candidates within its research pipeline.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
